Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibodies that combine tumor-targeting with tumor microenvironment modulation. Its lead candidate, BCA101, is a dual-action EGFR/TGF-β inhibitor in an open-label Phase 1/1b dose expansion being evaluated as monotherapy and in combination with pembrolizumab for frontline HPV-negative R/M HNSCC, advanced SqNSCLC, and cutaneous squamous cell carcinoma. Bicara presented positive interim clinical data at ASCO 2023 and ESMO 2023 demonstrating clinically meaningful anti-tumor activity and a tolerable safety profile in frontline HPV-negative R/M HNSCC. Additional data updates from the ongoing Phase 1/1b study, including in advanced SqNSCLC, are anticipated in 2024. Proceeds from the Series C financing will support continued advancement of BCA101. With the completion of the Series C, Bicara has raised $273 million in 2023. Bicara Therapeutics develops first-in-class bifunctional antibodies that combine targeted therapy precision with tumor modulators to deliver immunomodulatory payloads directly to the tumor microenvironment. Its lead asset, BCA101, is an EGFR / TGF-β-trap bifunctional antibody intended to inhibit EGFR and disable TGF-β at the tumor site to improve anti-tumor responses and the therapeutic window. BCA101 is currently enrolling patients in a Phase 1/1b study and the company has reported promising efficacy and safety data, with plans to present additional data at a medical conference in 2023. Bicara is also advancing IND-enabling studies for a second program, BCA356. The company says it intends to execute future clinical studies of BCA101 in the U.S. and Europe. Bicara is based in Cambridge, Mass.

Total raised

$273M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2023